<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02309827</url>
  </required_header>
  <id_info>
    <org_study_id>B7981001</org_study_id>
    <secondary_id>2014-004326-17</secondary_id>
    <secondary_id>PF-06651600</secondary_id>
    <secondary_id>JAK3</secondary_id>
    <nct_id>NCT02309827</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic Study of PF-06651600 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-06651600 In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a first in human study of PF-06651600. PF-06651600 is being developed for
      treatment of inflammatory bowel disease. This study will test single and multiple doses of
      PF-06651600. The goal of the study is to assess the safety, tolerability, pharmacokinetics
      and pharmacodynamics of PF-06651600 in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 hour creatinine clearance (Single Dose)</measure>
    <time_frame>Single dose period, Day 0 (baseline) and 24 hours post dose Day 1.</time_frame>
    <description>24 hour urine creatinine clearance in healthy subjects participating in the single dose periods. For the single dose period, assessment occurs on Study Days 0 and 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hour creatinine clearance (Multiple Dose)</measure>
    <time_frame>Multiple dose period, Days 0 (baseline), 7 and 14.</time_frame>
    <description>24 hour urine creatinine clearance in healthy subjects participating in the multiple dose period. For the multiple ascending dose period assessments occur on Study Days 7 and 14.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in urine volume (Single Dose)</measure>
    <time_frame>Single dose period, Day 0 (baseline) and 24 hours post dose Day 1.</time_frame>
    <description>For the single dose period, assessment occurs on Study Days 0 and 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in urine electrolytes (Single Dose)</measure>
    <time_frame>Single dose period, Day 0 (baseline) and 24 hours post dose Day 1.</time_frame>
    <description>For the single dose period, assessment occurs on Study Days 0 and 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in urine osmolality (Single Dose)</measure>
    <time_frame>Single dose period, Day 0 (baseline) and 24 hours post dose Day 1.</time_frame>
    <description>For the single dose period, assessment occurs on Study Days 0 and 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of urine volume (Multiple Dose)</measure>
    <time_frame>Multiple dose period, Days 0 (baseline), 7 and 14.</time_frame>
    <description>For the multiple ascending dose period assessments occur on Study Days 7 and 14.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of urine electrolytes (Multiple Dose)</measure>
    <time_frame>Multiple dose period, Days 0 (baseline), 7 and 14.</time_frame>
    <description>For the multiple ascending dose period assessments occur on Study Days 7 and 14.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in urine osmolality (Multiple Dose)</measure>
    <time_frame>Multiple dose period, Days 0 (baseline), 7 and 14.</time_frame>
    <description>For the multiple ascending dose period assessments occur on Study Days 7 and 14.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for PF-06651600 (Single Dose)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Maximum Observed Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for PF-06651600 (Multiple Dose)</measure>
    <time_frame>Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose)</time_frame>
    <description>Maximum Observed Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Cmax) for PF-06651600 (Single Dose)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Time to Reach Maximum Observed Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Cmax) for PF-06651600 (Multiple Dose)</measure>
    <time_frame>Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose)</time_frame>
    <description>Time to Reach Maximum Observed Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-06651600 (Single Dose)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06651600 (Single Dose)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Maximum Observed Plasma Concentration (Cmaxdn) for PF-06651600 (Single Dose)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Dose Normalized Maximum Observed Plasma Concentration (Cmaxdn)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Maximum Observed Plasma Concentration (Cmaxdn) for PF-06651600 (Multiple Dose)</measure>
    <time_frame>Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose)</time_frame>
    <description>Dose Normalized Maximum Observed Plasma Concentration (Cmaxdn)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinfdn) for PF-06651600 (Single Dose)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Dose Normalized Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinfdn)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClastdn) for PF-06651600 (Single Dose)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClastdn)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) for PF-06651600 (Single Dose)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Plasma Decay Half-Life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) for PF-06651600 (Multiple Dose)</measure>
    <time_frame>Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose)</time_frame>
    <description>Plasma Decay Half-Life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Resonance Time (MRT) for PF-06651600 (Single Dose)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Mean Resonance Time (MRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Resonance Time (MRT) for PF-06651600 (Multiple Dose)</measure>
    <time_frame>Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose)</time_frame>
    <description>Mean Resonance Time (MRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) for PF-06651600 (Single Dose)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) for PF-06651600 (Multiple Dose)</measure>
    <time_frame>Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose)</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance (CL/F) for PF-06651600 (Single Dose)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent total body clearance (CL/F) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance (CL/F) for PF-06651600 (Multiple Dose)</measure>
    <time_frame>Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose)</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent total body clearance (CL/F) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Concentration (Cmin) for PF-06651600 (Multiple Dose)</measure>
    <time_frame>Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose)</time_frame>
    <description>Minimum Observed Plasma Concentration (Cmin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Concentration for Dosing Interval (12 or 24 hours) (Cav) for PF-06651600 (Multiple Dose)</measure>
    <time_frame>Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose)</time_frame>
    <description>Average Concentration for Dosing Interval (12 or 24 hours) (Cav)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve for Dosing Interval (12 or 24 hours) for PF-06651600 (Multiple Dose)</measure>
    <time_frame>Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose)</time_frame>
    <description>Area Under the Curve for Dosing Interval (12 or 24 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Area Under the Curve for Dosing Interval (12 or 24 hours) for PF-06651600 (Multiple Dose)</measure>
    <time_frame>Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose)</time_frame>
    <description>Dose Normalized Area Under the Curve for Dosing Interval (12 or 24 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak to Trough Fluctuation (PTF) for PF-06651600 (Multiple Dose)</measure>
    <time_frame>Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose)</time_frame>
    <description>Peak to Trough Fluctuation (PTF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Accumulation Ratio (Rac) for PF-06651600 (Multiple Dose)</measure>
    <time_frame>Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose)</time_frame>
    <description>Observed Accumulation Ratio (Rac)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Accumulation Ratio for Cmax (RacCmax) for PF-06651600 (Multiple Dose)</measure>
    <time_frame>Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose)</time_frame>
    <description>Observed Accumulation Ratio for Cmax (RacCmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady State Accumulation Ratio (Rss) for PF-06651600 (Multiple Dose)</measure>
    <time_frame>Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose)</time_frame>
    <description>Steady State Accumulation Ratio (Rss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of PF-066561600 Excreted Unchanged (Multiple Dose)</measure>
    <time_frame>Day 14 (12, 24 hours post dose)</time_frame>
    <description>Concentration in urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of BCL2 gene expression in whole blood (Single Dose)</measure>
    <time_frame>Days -1 and 1 (0, 1, 2, 4, 8, 12 and 24 hours post dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of BCL2 gene expression in whole blood (Multiple Dose)</measure>
    <time_frame>Days 1, 5, 10, 14 (0, 1, 2, 4, 8, 12 and 24 hours post dose), 16, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of IP-10 protein concentration in serum (Multiple Dose)</measure>
    <time_frame>Days 0, 2, 7, 14 (0, and 16 hours post dose) and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of hsCRP protein concentration in serum (Multiple Dose)</measure>
    <time_frame>Days 0, 2, 7, 14 (0, and 16 hours post dose) and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of reticulocyte counts in whole blood (Single Dose)</measure>
    <time_frame>Days 0, 2, 3, and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of neutrophil counts in whole blood (Single Dose)</measure>
    <time_frame>Days 0, 2, 3, and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of hemoglobin level whole blood (Single Dose)</measure>
    <time_frame>Days 0, 2, 3, and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of reticulocyte counts in whole blood (Multiple Dose)</measure>
    <time_frame>Days 0, 4, 8, 12, 14 (pre-dose) 15, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of neutrophil counts in whole blood (Multiple Dose)</measure>
    <time_frame>Days 0, 4, 8, 12, 14 (pre-dose) 15, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of hemoglobin level in whole blood (Multiple Dose)</measure>
    <time_frame>Days 0, 4, 8, 12, 14 (pre-dose) 15, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (Multiple Dose)</measure>
    <time_frame>Day 1, Day 14 (12, 24 hours post dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of PF-066561600 Excreted Unchanged (Multiple Dose)</measure>
    <time_frame>Day 14 (12, 24 hours post dose)</time_frame>
    <description>Concentration in urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of IP-10 gene expression in blood (Multiple Dose)</measure>
    <time_frame>Days 0, 5, 10, 14 (0, 1, 2, 4, 8 and 12 hours post dose) and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of IP-10 gene expression in blood (Single Dose)</measure>
    <time_frame>Days 0, 1 (0, 1, 2, 4, 8 and 12 hours post dose) and 16</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1: PF-06651600 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: PF-06651600 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: PF-06651600 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: PF-06651600 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: PF-06651600 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: PF-06651600 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: PF-06651600 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8: PF-06651600 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9: PF-06651600 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06651600 or Placebo</intervention_name>
    <description>PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.</description>
    <arm_group_label>Cohort 1: PF-06651600 or Placebo</arm_group_label>
    <arm_group_label>Cohort 2: PF-06651600 or Placebo</arm_group_label>
    <arm_group_label>Cohort 3: PF-06651600 or Placebo</arm_group_label>
    <arm_group_label>Cohort 4: PF-06651600 or Placebo</arm_group_label>
    <arm_group_label>Cohort 5: PF-06651600 or Placebo</arm_group_label>
    <arm_group_label>Cohort 6: PF-06651600 or Placebo</arm_group_label>
    <arm_group_label>Cohort 7: PF-06651600 or Placebo</arm_group_label>
    <arm_group_label>Cohort 8: PF-06651600 or Placebo</arm_group_label>
    <arm_group_label>Cohort 9: PF-06651600 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male/female subjects between 18 and 55 years old, inclusive. Females must be
             of non-child bearing potential.

          -  BMI of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).

          -  Evidence of personally signed and dated informed consent document.

          -  Willing and able to comply with scheduled visits, treatment plan, lab tests and other
             study procedures.

          -  Subjects must avoid high intensity UV light exposure (eg, active sunbathing, tanning
             beds/booths or sunlamps) from the first dose of study drug and for the duration of the
             study.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, GI, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.

          -  Use of tobacco/nicotine containing products in excess of 5 cigarettes/day.

          -  History of regular alcohol consumption exceeding 14 drinks/week for females or 21
             drinks/week for males.

          -  Screening blood pressure &gt;140/90 mm Hg.

          -  Screening laboratory abnormalities as defined by the protocol.

          -  Unwilling or unable to comply with the Lifestyle Guidelines as defined by the
             protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7981001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2014</study_first_submitted>
  <study_first_submitted_qc>December 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2014</study_first_posted>
  <last_update_submitted>September 15, 2016</last_update_submitted>
  <last_update_submitted_qc>September 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammatory bowel disease</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

